Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Adam Currey
Institution:
Medical College of Wisconsin
Observed institutions:
Froedtert Hospital,
Medical College of Wisconsin
ORCID:
0000-0002-4099-712X
Observed ORCID:
0000-0002-4099-712X
OpenAlex ID:
A5131429653
Impact of Tamoxifen Only After Lumpectomy for “Good-Risk” Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials
2026
·
Jean L. Wright
, Jennifer Moughan
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
2
PDF
Receipt of guideline‐concordant local and chemotherapy‐based systemic therapy for patients with triple‐negative breast cancer: 10‐year survival outcomes in a multi‐state population‐based analysis
2026
·
Joseph Lipscomb
, Gretchen G. Kimmick
, et al.
·
Cancer
·
2
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
·
Cancer Research Communications
·
1
PDF
Supplementary Table 13 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 10 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 11 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 8 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Data from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 6 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 7 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 6 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Show more works
View as search
Works count:
31
Citation count:
5
H-index:
2
I10-index:
Year
Topic
Type